Skip to main content

Fungemia

4
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
micafunginPhase 31 trial
Non interventionN/A1 trial
Active Trials
NCT02555787Completed4,430Est. Sep 2022
NCT00794703Completed288Est. Nov 2009
Pfizer
PfizerNEW YORK, NY
2 programs
1
Active AnidulafunginPhase 31 trial
Voriconazole as Prophylaxis for Liver Transplant RecipientsN/A1 trial
Active Trials
NCT00177788Completed800Est. Aug 2012
NCT00806351Terminated21Est. Oct 2011
MSD
MSDIreland - Ballydine
2 programs
1
CaspofunginPhase 21 trial
Non interventionN/A
Active Trials
NCT01260974Unknown38Est. Nov 2012
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
CaspofunginPhase 2
Non interventionN/A
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
Non interventionN/A
Non interventionN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Non interventionN/A
Kite Pharma
Kite PharmaCA - El Segundo
1 program
Non interventionN/A1 trial
Active Trials
NCT01236261Completed730Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerActive Anidulafungin
Astellasmicafungin
MSDCaspofungin
AstellasNon intervention
Kite PharmaNon intervention
PfizerVoriconazole as Prophylaxis for Liver Transplant Recipients

Clinical Trials (6)

Total enrollment: 6,307 patients across 6 trials

NCT00806351PfizerActive Anidulafungin

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Start: Aug 2009Est. completion: Oct 201121 patients
Phase 3Terminated
NCT00794703Astellasmicafungin

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

Start: Nov 2008Est. completion: Nov 2009288 patients
Phase 3Completed
NCT01260974MSDCaspofungin

Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

Start: May 2009Est. completion: Nov 201238 patients
Phase 2Unknown
NCT02555787AstellasNon intervention

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients

Start: Mar 2015Est. completion: Sep 20224,430 patients
N/ACompleted
NCT01236261Kite PharmaNon intervention

Prospective Population Study on Candidemia in Spain

Start: Mar 2013Est. completion: Mar 2013730 patients
N/ACompleted
NCT00177788PfizerVoriconazole as Prophylaxis for Liver Transplant Recipients

Voriconazole as Prophylaxis for Liver Transplant Recipients

Start: Sep 2005Est. completion: Aug 2012800 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.